New COPD Treatments: Monthly Biologic Injections and Who Qualifies

For years, COPD treatment meant inhalers and not much else. That has changed.

Since 2024, the FDA has approved the first biologic injections for COPD, and one of them is given once a month. These medicines don't replace inhalers. They're added on top of them for people who still have flare-ups. This guide explains the newest COPD therapies, who qualifies, and how people pay for them.

Recent Breakthroughs in COPD Treatment

Most COPD medicines open the airways. The newest ones go after the inflammation that drives flare-ups. Two biologics are now approved in the U.S. for a specific type of COPD called eosinophilic COPD.

Eosinophils are white blood cells linked to airway inflammation, and a simple blood test shows whether your levels are high.

• Mepolizumab (Nucala): approved for COPD in May 2025. It's an injection under the skin given once every four weeks, which is where the "monthly injection" comes from.
• Dupilumab (Dupixent): approved for COPD in September 2024 as the first biologic for the disease. It's injected under the skin every two weeks.

Both are add-on maintenance treatments for adults whose COPD isn't well controlled on inhalers. In clinical trials, adding either one to inhaled therapy reduced moderate and severe flare-ups compared with placebo. Neither one is a cure, and neither replaces your inhalers.

There's also a newer non-biologic option. Ensifentrine (Ohtuvayre), approved in 2024, is a maintenance medicine taken through a nebulizer. It works differently from traditional inhalers, and doctors can add it to an existing regimen.

How Monthly Biologic Injections Work

Biologics are made from living cells and are designed to block one specific part of the immune response. Mepolizumab targets interleukin-5 (IL-5), a signal that helps eosinophils grow and survive. Dupilumab blocks signals from IL-4 and IL-13, two drivers of a type of inflammation called type 2 inflammation.

Many patients learn to give the injection at home with a prefilled pen or syringe after training from their care team. Others get it at a doctor's office. Results aren't immediate. Doctors usually judge the benefit over several months by tracking flare-ups, symptoms and lung function.

COPD Patient Eligibility: Who Qualifies for a Biologic?

Biologics are meant for a specific group of patients, not everyone with COPD. Doctors generally look for:

• A COPD diagnosis confirmed by breathing tests (spirometry).
• Flare-ups despite inhaled therapy. Most people in the trials were already on triple therapy and still had exacerbations.
• An eosinophilic phenotype, measured with a blood eosinophil count. Mepolizumab was studied in patients with counts as low as 150 cells per microliter. Dupilumab's trials enrolled patients with 300 or more.
• Insurance criteria, which often require documented flare-ups, recent lab results and proof that inhaled treatment wasn't enough.

If you've had steroid bursts, antibiotics or hospital visits for COPD in the past year, ask your doctor whether an eosinophil count makes sense. A pulmonologist can confirm whether you're a candidate.

Triple Therapy COPD Inhalers Come First

Biologics are added to inhalers, not used instead of them. Triple therapy combines three medicines, usually in one inhaler: an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist (LAMA). Most people who qualify for a biologic are already using triple therapy or have tried it.

That means inhaler costs stay part of the picture. Our guide to COPD inhalers covered by Medicare explains which inhalers plans typically cover and what you may pay.

Paying for New COPD Therapies

Biologics are expensive, with list prices in the thousands of dollars per dose. Most people pay far less, but how much depends on their coverage.

• Medicare: biologics you inject at home are usually covered under Part D. Those given in a doctor's office may be billed under Part B. Part D now has an annual out-of-pocket cap, which limits what you pay for covered drugs in a year.
• Private insurance: plans usually require prior authorization. Manufacturer copay programs can lower costs for many commercially insured patients, though they generally can't be used with Medicare or Medicaid.
• Patient assistance programs: drug makers and independent charitable foundations run programs that may provide free or low-cost medicine to people who meet income and insurance requirements. Some cover COPD inhalers as well as biologics.
• Medicaid: coverage varies by state, and prior authorization is common.

Ask your doctor's office whether it has a benefits coordinator. Many specialty practices handle prior authorization and assistance applications for patients.

COPD Clinical Trials and Research Projects

Researchers are testing more biologics that target other inflammation pathways, including options for people without high eosinophil counts. Clinical trials and COPD research projects are one way to get access to investigational treatments.

COPD clinical trial eligibility depends on the study. Common requirements include age, how severe your COPD is, smoking history, flare-up history and blood test results. You can search ClinicalTrials.gov, the federal registry of U.S. studies, by condition and location, or ask your pulmonologist about studies nearby. Trials are voluntary, and you can leave at any time.

Questions to Ask Your Doctor

1. Have my flare-ups in the past year been frequent enough to consider a biologic?
2. Should I get a blood eosinophil count?
3. Is my inhaler regimen optimized, and am I using my inhaler correctly?
4. Which biologic fits my situation, and how often would I need injections?
5. What will my insurance require, and is there an assistance program I might qualify for?
6. Are there clinical trials I could join?

Frequently Asked Questions

Is there a monthly injection for COPD?

Yes. Mepolizumab (Nucala) is given once every four weeks as an add-on treatment for adults with eosinophilic COPD that isn't well controlled. Dupilumab (Dupixent) is given every two weeks.

Can a biologic replace my inhalers?

No. Both approved COPD biologics are add-on treatments. You'll keep using your maintenance inhalers unless your doctor tells you otherwise.

What are the common side effects?

Reported side effects include injection-site reactions, headache and cold-like symptoms. Serious allergic reactions are rare but possible. Your doctor can explain the risks for each medicine.

Will a biologic cure COPD?

No. COPD has no cure. Biologics aim to reduce flare-ups in people who qualify, alongside inhalers, pulmonary rehabilitation and quitting smoking.

For day-to-day habits that help with breathing, see our chronic lung disease management guide.

This article is general information only and is not medical advice. Talk with your doctor before starting or changing any COPD treatment.